{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:06:10Z","timestamp":1791655570255,"version":"4.3.4"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T00:00:00Z","timestamp":1552953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Lessons Learned<\/jats:title>\n                  <jats:p>The results of the APPEARANCE trial indicate that adapalene does not prevent acne-like rash over placebo when added to topical moisturizer and oral minocycline but instead may have a detrimental effect. Therefore, adapalene is not recommended as prophylaxis against acne-like rash induced by anti-epidermal growth factor receptor therapies. Given that acne-like rash was completely controlled with placebo in approximately half of patients, predictive measures to identify patients needing intensive prophylaxis are required.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Anti-epidermal growth factor receptor (EGFR) therapies are frequently associated with acne-like rash. To evaluate the prophylactic efficacy of adapalene, a topical retinoid used as first-line therapy for acne vulgaris, we conducted a randomized, placebo-controlled, evaluator-blinded, left-right comparative trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with non-small cell lung, colorectal, or head and neck cancer scheduled to receive anti-EGFR therapies were randomly assigned to once-daily adapalene application on one side of the face, with placebo on the other side. All patients had topical moisturizer coapplied to both sides of the face, and received oral minocycline. The primary endpoint was the difference in total facial lesion count of acne-like rash at 4\u2009weeks. Secondary endpoints included complete control rate (CCR) of acne-like rash (\u22645 facial lesions) and global skin assessment (Investigator's Global Assessment [IGA] scale, grade 0\u20134) at 4\u2009weeks. Two blinded dermatologists independently evaluated the endpoints from photographs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 36 patients were enrolled, of whom 26 were evaluable. Adapalene treatment was associated with a greater lesion count than placebo at 4\u2009weeks, although the difference was not statistically significant (mean, 12.6 vs. 9.8, p\u2009=\u2009.12). All four patients with a difference &amp;gt;10 in lesion count between face sides had a greater count on the adapalene-treated side. No significant differences were observed in CCR of acne-like rash (54% vs. 50%) or IGA scale (mean grade, 1.9 vs. 1.7) between the adapalene and placebo sides.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Adapalene is not recommended as prophylaxis against acne-like rash induced by anti-EGFR therapies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0156","type":"journal-article","created":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T19:46:34Z","timestamp":1553024794000},"page":"885-e413","source":"Crossref","is-referenced-by-count":17,"title":["Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti-Epidermal Growth Factor Receptor-Induced Acne-Like Rash: A Randomized Left-Right Comparative Evaluation (APPEARANCE)"],"prefix":"10.1093","volume":"24","author":[{"given":"Naoko","family":"Chayahara","sequence":"first","affiliation":[{"name":"Division of Medical Oncology and Hematology, Kobe University Graduate School of Medicine, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Mukohara","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Kobe University Graduate School of Medicine, Kobe, Japan"},{"name":"Division of Cancer Center, Kobe University Hospital, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoko","family":"Tachihara","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimi","family":"Fujishima","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Kobe University Graduate School of Medicine, Kobe, Japan"},{"name":"Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Fukunaga","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Internal related, Kobe University Graduate School of Medicine, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Washio","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Internal related, Kobe University Graduate School of Medicine, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyosuke","family":"Nakata","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Takenaka","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Kobe University Graduate School of Medicine, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Toyoda","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Kobe University Graduate School of Medicine, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Kiyota","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Kobe University Graduate School of Medicine, Kobe, Japan"},{"name":"Division of Cancer Center, Kobe University Hospital, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Tobimatsu","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisayo","family":"Doi","sequence":"additional","affiliation":[{"name":"Department of Nursing, Kobe University Hospital, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Mizuta","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Kobe University Hospital, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naho","family":"Marugami","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Kobe University Hospital, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Education and Research Center for Community Medicine, Faculty of Medicine, Saga University, Saga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikako","family":"Nishigori","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Internal related, Kobe University Graduate School of Medicine, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Minami","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Kobe University Graduate School of Medicine, Kobe, Japan"},{"name":"Division of Cancer Center, Kobe University Hospital, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,3,19]]},"reference":[{"key":"2021122507124533300_R1","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1002\/cncr.25090","article-title":"Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life","volume":"116","author":"Joshi","year":"2010","journal-title":"Cancer"},{"key":"2021122507124533300_R2","first-page":"34","article-title":"Dermatologic toxicities associated with EGFR inhibitors: The clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae","volume":"21","author":"Wagner","year":"2007","journal-title":"Oncology (Williston Park)"},{"key":"2021122507124533300_R3","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","article-title":"Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor","volume":"22","author":"Saltz","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122507124533300_R4","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer","volume":"22","author":"Perez-Soler","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122507124533300_R5","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","article-title":"Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption","volume":"25","author":"Scope","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122507124533300_R6","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","article-title":"Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer","volume":"28","author":"Lacouture","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122507124533300_R7","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00520-011-1197-6","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture","year":"2011","journal-title":"Support Care Cancer"},{"issue":"suppl 3","key":"2021122507124533300_R8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.0926-9959.2001.00006.x","article-title":"Adapalene biochemistry and the evolution of a new topical retinoid for treatment of acne","volume":"15","author":"Czernielewski","year":"2001","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2021122507124533300_R9","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaad.2006.06.046","article-title":"Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy","volume":"56","author":"DeWitt","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"2021122507124533300_R10","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/j.1346-8138.2011.01424.x","article-title":"Successful treatment with adapalene of cetuximab-induced acneiform eruptions","volume":"39","author":"Taguchi","year":"2012","journal-title":"J Dermatol"},{"key":"2021122507124533300_R11","doi-asserted-by":"crossref","first-page":"978","DOI":"10.2482\/haigan.54.978","article-title":"Successful treatment with adapalene for EGFR-TKI-induced acneiform eruptions","volume":"54","author":"Tachihara","year":"2014","journal-title":"Jpn J Lung Cancer"},{"key":"2021122507124533300_R12","doi-asserted-by":"crossref","first-page":"ix514","DOI":"10.1016\/S0923-7534(20)34145-4","article-title":"Prophylactic topical adapalene and oral minocycline for panitumumab-induced skin toxicity","volume":"23","author":"Yanai","year":"2012","journal-title":"Ann Oncol"},{"issue":"suppl 6","key":"2021122507124533300_R13","first-page":"s18","article-title":"Adapalene 0.1% gel compared to tazarotene 0.1% cream in the treatment of acne vulgaris","volume":"7","author":"Pariser","year":"2008","journal-title":"J Drugs Dermatol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0156","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0156","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/7\/885\/41918440\/oncolo_24_7_885.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/7\/885\/41918440\/oncolo_24_7_885.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T07:13:49Z","timestamp":1640416429000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/7\/885\/6439409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,19]]},"references-count":13,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,3,19]]},"published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0156","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7,1]]},"published":{"date-parts":[[2019,3,19]]}}}